Signature Equity Partners’s AbbVie ABBV Stock Holding History

Signature Equity Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$330K	Sell	1,310 -189	-13%	-$40.7K	0.15%	139
2026 Q1	$326K	Sell	1,499 -95	-6%	-$21.1K	0.18%	124
2025 Q4	$364K	Buy	+1,594	New	+$363K	0.2%	105

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Signature Equity Partners's ABBV Position: Q2 2026 in Review

Signature Equity Partners reduced its AbbVie (ABBV) stake by 13% in Q2 2026, selling an estimated $40.7K and leaving 1,310 shares worth $330K. The position accounts for 0.15% of the portfolio, ranked #139.

Signature Equity Partners first reported a position in ABBV in Q4 2025 and has held it in 3 quarters since. The position peaked at $364K in Q4 2025. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Signature Equity Partners held 1,310 shares of AbbVie worth $330K as of Q2 2026.
Signature Equity Partners sold 189 AbbVie shares in Q2 2026, an estimated $40.7K.
AbbVie made up 0.15% of Signature Equity Partners's portfolio in Q2 2026, its #139 holding.
Signature Equity Partners first reported a position in AbbVie in Q4 2025 and has held it in 3 quarters since.
Signature Equity Partners's AbbVie position peaked at $364K in Q4 2025.
4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Signature Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.